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ABSTRACT 
DANAZOL AS A STEROID ENZYME INHIBITOR 
IN RAT ADRENAL GLANDS 
Frank A. Miklavcic 
Morehead State Univ 
Director of Thesis: 
The effect of Danazol, a synthe ic steroid deriva-
tive, as an inhibitor of the enzymes of st·eroidogenesis, 
was studied in the adrenal glands of adult female rats 
in vivo. Analysis was made of adrenal weight, zona 
glomerulosa histology, and electrolyte concentration in 
the urine and blood plasma. 
Changes in sodium, potassium, and chloride ion 
concentrations in the urine and plasma of Danazol inject-
ed rats with ovaries intact suggest the possible inhibi-
tion of the synthesis of aldo?terone. However, castrated 
rats injected with Danazol exhibited no differences in 
the characteristics analyzed when compared to the castrate 
control group. This suggests that Danazol may affect the 
adrenal glands by way of its influence on estrogen 
release from the ovary. Another explanation may be that 
estrogens have a permissive action on the means by which 
Danazol affects the adrenals. 
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INTRODUCTION 
Danazol, a 2,3-isoxazol derivative of ethinyl 
testosterone, was developed by Manson, et al. ll-963) at 
Sterling-Winthrop Research Institute. The chemical name 
for Danazol (brand name Danocrine) is 17a-pregn-2,4-
dien-20-yno-[2,3-d]-isoxazol-17-ol. It has the basic 
structure of testosterone along with an ethinyl group 
at C-17 and an isoxazol ring replacing the keto group 
at C-3 (Figure 1.). 
According to Dmowski, et al. (1979) Danazol is 
currently approved by the Food and Drug Administration 
for use in the treatment of endometriosis. Clinically 
it has also been used for the treatment of chronic 
cystic mastitis, gynecomastia, precocious puberty, 
congenital angioneurotic edema, and as a male and female 
contraceptive. Danazol, if taken orally, is absorbed 
through the gastro-intestinal tract and metabolized 
quickly in the body, having a half-life of 4.5 hours in 
humans and reaching a peak in human female plasma two 
hours after administration. In monkeys and rats, however, 
plasma peak was reached four to eight hours after 
administration. 
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Chemical Structure of Danazol 
Figure 1. 
Danazol is metabolized in the liver by the cleavage 
of the isoxazol ring with over sixty of its metabolites 
having been isolated, the major one being 2-hydroxy-
methylethisterone. According to Rosi, et al. (1977), 
Danazol, rather than one of its metabolites, appears to 
cause the biologic effects. None of the metabolites 
exhibited the antigonadotropic or androgenic activities 
of Danazol, and when Danazol was administered with its 
metabolic blockers, its biological activities greatly 
increased. In studies with radioactive Danazol, high 
concentrations of radioactivity were noted in the liver, 
kidneys, and adrenals when compared to the concentration 
in the blood plasma. 
When Danazol was first marketed, advertising and 
pharmacological bulletins indicated that the primary 
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effect was suppression of the pituitary-ovarian axis by 
inhibiting the secretions of the gonadotropins FHS and LH 
from the pituitary. According to Dmowski, et al. (1977), 
Danazol appeared to have no progestational or estrogenic 
effect and only mildly androgenic side effects, which 
appeared in the form of acne, edema, mild hirsutism, and a 
decrease in breast size. Barbieri, et al. (1979) have 
stated that studies actually indicated that Danazol has at 
least four pharmacological properties: 1) direct 
inhibition of gonadotropin synthesis and/or release, 2) 
direct inhibition of the multiple enzymes of steroido-
genesis, 3) interaction with androgen, glucocorticoid, and 
progesterone receptors in target tissues, and 4) 
alteration bf endogenous steroid metabolism. 
The antigonadotropic effect of Danazol was 
reported by Greenblatt and Dmowski (1971) because it had 
no effect when administered with exogenous gonadotropins. 
Greenblatt, et al. (1974) indicated the possible use of 
-
Danazol as a contraceptive agent because of the drop in 
FSH and LH levels at a dosage of 100 mg per day and, in 
particular, the prevention of the mid-cycle LH surge 
prior to ovulation. Van Dijk, et al. (1979) have used 
Danazol for treating unexplained infertility in women. 
Women with infertility diagnosed as unexplainable by all 
known clinical tests were administered Danazol orally with 
a control group receiving placebos. Anovulation occurred, 
and upon cessation of treatment, a significant number of 
the treated group conceived within six months while none 
of the placebo group did. No explanation as to why 
conception occured was discernible. Franchimont and 
Cramilion (1977) reported that FSH and LH were the only 
hormones of the anterior pituitary inhibited, as no 
changes in the response of ACTH, TSH, or prolactin were 
noted. 
Mild androgenic effects have been observed 
clinically, especially at higher doses, but more anabolic 
rather than androgenic effects seem to appear at these 
higher doses. Barbieri, et ~- (1979) have done 
extensive work on the receptor binding ability of Danazol 
and have noted that Danazol displaces 311-dihydrotesto-
sterone from the 8S androgen receptor of the prostate 
cytosol along with positive results of the androgen 
bioassay using ventral prostate and seminal vesicle 
weights. This receptor binding correlates with the mild 
androgenic side effects. Potts, et al. (1974) have 
referred to Danazol as an impeded androgen since a high 
dose of 672 mg/kg/day produced effects comparable to a 
low dosage of only 84 mg/kg/day. 
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Danazol exhibits no estrogenic effects. Barbieri, 
et al. (1979) reported slight gains in uterine weights in 
immature female rats, but when compared to the effect 
produced by the estrogen compound mestranol, Danazol 
produced less of a uterine weight gain at ten thousand 
times the concentration of mestranol. They also noted 
that no vaginal cornification occurred at a dosage of 
40 mg/kg/day. In correlation Danazol bound only very 
weakly to the rat uterine cytosol in displacing 3H-estra-
diol. Potts, et al. (1974) compared the slight uterine 
weight gain to that caused by androgens. 
Whether Danazol is a progestational or anti-progest-
ational agent still remains controversial. While Potts, 
et al. (.1974) showed that Danazol has no progestational 
effect in the Clauberg assay, Dmowski, et al. (1971) and 
Wentz and Sapp (1978) have reported endometrial secretory 
changes with Danazol treatment, although the changes were 
atypical of those induced by progesterone. Creange, 
et al. (1974) developed a radioligand assay for Danazol 
using a protein which has a high specificity for 
progesterone. In determining the effect of Danazol as a 
luteolytic contraceptive, however, Wentz and Sapp (1978) 
reported a rise in progesterone levels following HCG 
injections after Danazol treatment, indicating that 
Danazol does not have the luteolytic effect of 
5 
progesterone. The~e facts plus the reported evidence by 
Barbieri, et al. (1979) that Danazol binds to the rat 
uterine cytosol receptor leave the progestational-
antiprogestational controversy still be researched 
further. 
Barbieri, et al. (1979) have demonstrated the 
glucocorticoid effect of Danazol by the liver glycogen 
assay and by the ability of Danazol to bind to the 
glucocorticoid receptor of the rat liver cytosol. 
Franchimont and Cramilion (1977) showed that serum 
cortisol levels were significantly lower in Danazol 
treated patients; however, Wentz, et al. (1975) have 
reported that Danazol has no apparent effect on the 
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adrenal gland's ability to respond to ACT!!. Their methods 
included the injection of the synthetic ACTH compound 
cosyntropin in Danazol treated patients as well as the 
injection of the 118-hydroxylase inhibitor metyrapone. 
The cosyntropin challenge produced an increase in plasma 
cortisol levels, and the metyrapone challenge caused a rise 
in 17-hydroxysteroid levels. 
Barbieri, et al. (1977) have reported the inhibition 
of steroidogenesis in hamster ovaries, rat testes, and 
rat adrenals in vitro. In rat adrenals the 38-hydroxy-
steroid dehy,drogenase and 21-hydroxylase enzymes of the 
cytoplasm and the 118-hydroxylase enzyme of the mite-
chondria are inhibited by Danazol. He mentioned that a 
number of previous reports of antigonadotropic effects by 
Dmowski, et al. (1971) and Potts, et al. (1974) in 
hemicastrates and castrates could actually have been 
caused by the inhibition of steroidogenesis. Sherins, 
et al. (1971) also noted changes in gonadal steroid levels 
in humans with no corresponding FSH or LH changes. 
There are four main groups of adrenal cortical 
steroids (Greenberg, 1968): 1) the 11-oxygenated 
corticosteroids or glucocorticoids which affect carbo-
hydrate metabolism and include primarily cortisol, 
corticosterone, 11-dehydrocorticosterone and cortisone, 
2) the corticoids lacking oxygen at C-11 or mineralo-
corticoids which include 11-deoxycorticosterone (DOC), 
and 11-deoxycortisol, 3) aldosterone which is the most 
potent steroid involved in electrolyte metabolism and has 
an aldehyde group at C-18, and 4) the sex steroids. 
Since the adrenal cortex, testes, ovaries, and 
placenta are all centers of steroid synthesis, it has 
been shown that they all contain the same enzyme systems. 
The C-27 molecule cholesterol is the precursor of almost 
fifty different steroids produced by the adrenal cortex. 
The first step is the conversion of cholesterol to the 
C-21 molecule pregnenolone by a cytochrome P-450 enzyme of 
the mitochondria which requires NADPH and molecular oxygen 
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and cleaves the side chain from cholesterol. The side 
chain cleavage step appears to be the rate limiting step 
in steroid biosynthesis (Figure 2, Boyd, et al. (1978). 
Pregnenolone can be converted to either progesterone 
or 17a-pregnenolone. The pathways from 17a-pregnenolone 
lead to synthesis of the androgens and estrogens, but only 
the pathways leading to the mineralocorticoids and the 
glucocorticoids will be discussed here. 
Pregnenolone is converted to progesterone by 
38-hydroxysteroid dehydrogenase requiring NAD+ as a 
hydrogen acceptor and ~5-3-oxoisomerase which shifts the 
double bond from the numbers 5 and 6 carbons to the 
numbers 4 and 5 carbons. Progesterone can then be 
converted to 17a-hydroxyprogesterone by a 17a-hydroxylase 
associated with the cytoplasm. This pathway is prevalent 
in humans but does not exist in rats. A microsomal 
21-hydroxylase then converts 17a-hydroxyprogesterone to 
11-deoxycortisol, a mineralocorticoid which is then 
converted by the mitochondrial cytochrome P-450 118-
hydroxylase system to cortisol, the primary glucocorticoid 
in humans. 
Another pathway from progesterone, the primary one 
in rats, has a 21-hydroxylase product, 11-deoxycorticoster-
one (DOC), a mineralocorticoid comparable to 11-deoxy-
cortisol. DOC is then converted by the 118-hydroxylase to 
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Some Major Enzymes in the 
Biogenesis of Adrenal Cortical Hormones 
Figure 2. 
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corticosterone, the primary glucocorticoid in rats. 
Corticosterone can then be converted to the very potent 
mineralocorticoid aldosterone by 18-hydroxylase and 
18-hydroxy dehydrogenase found in the mitochondria. Once 
synthesized, aldosterone can be found either in the 
18-aldehyde form or in the more common 11-18 hemiacetal 
form. 
Sabatini and DeRoberts (1961) reported that, while 
3S-hydroxysteroid dehydrogenase, llS-hydroxylase, and 
21-hydroxylase activity occur throughout the cortex, the 
18-oxygenation to aldosterone is located only in the 
outer most zona glomerulosa, and the 17-hydroxylase 
activity is localized in the inner zona fasciculata or 
the zona reticularis. They originally reported the 
transformation of the zona glomerulosa into fasciculata 
cells upon chronic administration of ACTH, but more 
recently it has been shown that the zona glomerulosa and 
zona reticularis are independent of each other (Turner 
10 
and Bagnara, 1976). Watanuki, et al. (1978) have provided 
evidence that the llS-hydroxylase and 18-hydroxylase 
activities, which are part of the cytochrome P-450 complex, 
are actually catalyzed by only one enzyme. 
It is the purpose of this research to further 
explore the effects of Danazol on the rat adrenal cortex. 
This will be done by studying the effects of Danazol 
11 
on adrenal weight, electrolyte concentrations in the urine 
and blood, and the histology of the zona_ glomerulosa. 
Electrolyte levels to .be analyzed are sodium, potassium, 
and chloride concentrations. The first experiment will 
analyze the dosage level effect on these characteristics 
related to adrenal cortical steroidogenesis. From this an 
optimal dosage will be chosen to be used in a prolonged 
study of adrenal cortical response to Danazol. 
MATERIALS AND METHODS 
Animal Care 
Two experiments were performed on adult female 
Sprague-Dawley rats. The rats were housed three per 
12 
cage at 23° C. under a regimen of ten hours darkness and 
fourteen hours of artificial lighting. They were allowed 
access to water and Purina Rat Chow ad libitum. 
Experiment I 
Twelve rats were injected with Nembutal (4 mg/ 100 gm 
body weight) and ovariectomized. Four days following sur-
gery, the rats were divided into four groups and injected 
in the hind leg with Danazol (Sterling-Winthrop Labs) 
dissolved in peanut oil with Groups 2,3, and 4 receiving 
2,4, and 8 mg/kg body weight/day respectively and Group 1 
receiving a corresponding injection of peanut oil as a 
control. Four groups of rats with ovaries intact were 
injected with doses corresponding to Groups 1,2,3, and 4. 
Injections of all eight groups were continued for ten 
days. On the tenth day urine samples were taken by 
applying pressure in the area of the kidneys. Urine 
samples were stored in disposable culture tubes and 
frozen. Twenty four hours following the final injection, 
the rats were removed from the rat room in groups of 
three, stunned and decapitated within two minutes of 
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removal from the quarters to prevent the influence of 
ACTH release into the bloodstream. Blood was drained 
from the necks into 400 ml beakers, transferred to 15 ml 
disposable centrifuge tubes, centrifuged for 15 minutes 
at 1550 rpm, and the plasma frozen. The right adrenal 
was removed and placed in fixative to prevent degrada-
tion of the zona glomerulosa. The left adrenal was 
weighed, as were the ovaries of the intact• rats. 
The right adrenal was treated for removal of mercury 
with a saturated iodine-alcohol solution, dehydrated in 
alcohol and toluene, embedded in paraffin, sectioned at 
ten microns, stained with Delafield's hematoxylin, and 
counterstained with eosin by the method of Humason (1972). 
The zona glomerulosa thickness was measured under l00X 
with an optical micrometer. 
Ten lambda samples of urine and one hundred lambda 
samples of serum were measured for chloride ion concentra-
tion with a digital chloridometer (Buchler). Twenty 
lambda samples of urine and fifty lambda samples of serum 
were analyzed for sodium and potassium ion levels by 
flame photometry (Coleman Model 21). 
Experiment Il_ 
Twelve adult female rats were ovariectomized as per 
Experiment I. Four days following surgery, six castrated 
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females were injected with peanut oil as a control, while 
six were injected with a dosage of 4 mg/kg/ Body weight of 
Danazol dissolved in peanut oil. Two groups of six rats 
each with ovaries intact were. given corresponding injections. 
Injections were continued for twenty days. Post treatment 
protocol was followed as in Experiment I. 
Analysis of Data 
All data was analyzed using the Student's t test. 
RESULTS 
Experiment I 
Danazol caused no significant change in body weight 
in adult female rats, castrated or not, at the doses 
administered during the ten day experiment (Table 1). 
A significant increase in adrenal weight was 
observed in the castrate control group compared to the 
intact controls (Table 1). 
This experiment showed the most measurable effects 
of Danazol at a dosage of 4 mg/kg which corresponds to 
the reported dosage used by Dmowski, et al. (1971). At 
this dosage adrenal weight decreased compared to the 
control in castrates only, while intact rats showed a 
significant decrease in ovarian weight (Table 1). This 
dosage also caused an elevation of the serum Na+ levels 
and a decrease in Na+/K+ ratios (Table 2), as well as an 
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+ elevation of the urine Na levels in intact rats compared 
to the intact controls (Table 2). Castrates at the 4 mg/kg 
dosage exhibited a lowering of the serum K+ levels and 
an increase in the Na+/K+ ratios compared to the intact 
rats receiving this dosage (Table 2). 
A dosage of 2 mg/kg produced an increase in the 
Na+;K+ ratios in castrates compared to intact rats 
receiving this injection (Table 2), while a dosage of 
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TABLE 1. 
EXPERIMENT I 
BODY WEIGHT CHANGE AND RELATIVE ADRENAL AND OVARIAN WEIGHTS 
Dosage (mg/kg * Change in Body *Relative Adrenal 
body weight) Weight Weight (mg/ 100 
(gm) body weight) 
0 +10 ± 19 10.7 
2 +10 ± 21 8.0 
4 -7 ± 7 6.1 
8 +3 ± 5 9.4 
0 -2 ± 4 6.9 
2 +3 ± 5 6.2 
4 -4 ± 4 7.8 
8 +4 ± 7 6.2 
*Mean± Standard Deviation 
(a P<.02 compared to Intact· Control) 
(b P£.02 compared to Castrate Control) 
(C P£.05 compared to Intact Control) 
± 1. 3a 
+ 1. 2 
± 1. 4b 
± 2.3 
± 0.8 
± 1.0 
± 0.3 
± 1. 2 
*Relative Ovarian 
gm Weight (mg/ 100 
body weight) 
6.4 + 0.9 
4.5 ± 1. 2 
4.8 + 0.5c 
5.4 ± 1.1 
gm 
Dosage (mg/kg 
body weight) 
0 
µ:i 
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TABLE 2. 
EXPERIMENT I 
ION CONCENTRATIONS AND RATIOS IN THE BLOOD 
Na+ 
(meq/ 1) 
* 
109 t 67 
152 t 33 
150 t 13 
120 t 26 
118 t 30 
102 t 28 
83 t 3a 
90 t 10 
K+ 
(meq/1) 
* 
13.0 t 4.6 
12.0 t 2.6 
15.3 t 2. 0 
19.7 + 6. 9 
16.3 t 2. 3 
16.7 t 4.4 
21.0 t o.ob,c 
21. 0 ± 3.6 
c1-
(meq/ 1) 
* 
81 t 17 
67 t 16 
80 t 3 
78 t 8 
81 t 14 
84 t 15 
86 t 8 
88 t 14 
* Mean± Standard Deviation 
ca P.::: . 01 compared to dosage of 4 mg/kg in castrates) 
( b P.::: . 01 compared to intact control) 
cc po<: .02 compared to dosage of 4 mg/kg in castrates) 
Cd P .c:. 02 compared to dosage of 2 mg/kg in castrates) 
* 
7.1 t 3.4 
12.7 t 1. 4 
9.9 t 1.5 
6.4 t 1.5 
7.3 t 0. 8 
6.4 t 2.0d 
4.0 t o.sa,b 
4.4 t 1. 2 
I-' 
---, 
TABLE 3. 
EXPERIMENT I 
ION CONCENTRATIONS AND RATIOS IN THE URINE 
Dosage (mg/kg 
body weight) 
~ 0 
E-< 
<r: 2 pc: 
E-< 
(f) 
4 <r: 
u 
8 
0 
E-< 
u 2 <r: 
E-< 
z 
H 4 
8 
Na+ 
(meq/1) 
* 
118 ± 71 
179 ± 42 
175 + 13 
156 ± 43 
143 ± 19 
171 ± 28 
216 ± 27 
191 ± 19 
74 
114 
175 
155 
174 
140 
a 184 
a 169 
*Mean± Standard Deviation 
ca P ~. 02 compared to Intact (b P..:::: . 01 compared to Intact 
± 68 
± 46 
± 53 
± 22 
± 23 
± 40 
± 18 
± 31 
Control) 
Control) 
ci-
(meq/1) 
* 
131 ± 127 
186 ± 105 
194 ± 45 
227 ± 69 
195 + 18 
-
196 ± 60 
288 ± 70 
263 ± 6b 
* 
1. 9 ± 0.8 
1. 7 + 0.4 
-
1.0 ± 0. 5 
1.0 + 0. 5 
0.8 ± 0.6 
1. 3 + 0.4 
1. 2 + 0.3 
-
1. 2 ± 0.1 
f--
00 
eight mg/kg significantly elevated urine Na+ and Cl-
levels in intact females only (Table 3). 
Experiment II 
Administration of Danazol over a twenty day period 
again produced no significant change in body weight at 
any of the doses administered (Table 4). 
Injections of Danazol for twenty days caused a 
decrease in adrenal weights in both treated groups, but 
the castrate control group also exhibited a decrease in 
weight which was not significantly different from that of 
treated castrates (Table 4). Intact rats injected with 
Danazol exhibited a significantly lower ovarian weight 
compared to the intact control rats (Table 4). 
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+ . Danazol also caused an elevation of serum K levels 
. + + 
and a decrease in the Na /K ratios in the serum of intact 
rats (Table S), but the effect of castration alone was 
to elevate the serum K+ levels (Table S) as well as the 
levels of urine chloride ions (Table 6). 
Zona glomerulosa thickness decreased in both groups 
treated with Danazol compared to the intact control 
group, but castration alone also caused the glomerulosa 
layer to diminish in size (Table 7). 
Finally it should be noted that in all the data 
obtained (adrenal weight, ion concentrations and ratios, 
and thickness of the zona glomerulosa) not one significant 
difference was observed between Danazol injected castrates 
and control castrates. 
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TABLE 4. 
EXPERIMENT II 
BODY WEIGHT CHANGE AND RELATIVE ADRENAL AND OVARIAN WEIGHTS 
Treatment 
Intact Control 
*Change in Body 
Weight 
(gm) 
-1., 10 
*Relative Adrenal 
Weight (mg/ 100 gm 
body weight) 
9.7., 0.2 
*Relative Ovarian 
Weight (mg/ 100 gm 
body weight) 
11.4 ± 2.5 
--------------------------------------------------------------------------------
Intact Danazol +8., 14 
Castrate Control -5 ± 15 
Castrate Danazol -2 ± 10 
*Mean± Standard Deviation 
a 7.0 ± 1.3 
a 7.1 t 0.4 
(a P .C::. 001 compared to Intact Control) 
(b p,.::.. 01 compared to Intact Control) 
b 6.9 ± 1.6 
N 
)-J 
TABLE 5. 
EXPERIMENT II 
ION CONCENTRATIONS AND Na+/K+ RATIOS IN THE BLOOD 
Treatment 
Intact Control 
Intact Danazol 
Na+ 
(meq/1) 
* 
109.l ± 9.2 
119.3 ± 7.6 
Castrate Control 117.0 ± 13.1 
Castrate Danazol 113.4 ± 9.5 
K+ 
(meq/1) 
* 
13.5 ± 3.5 
21.3 "!: 4.7 a 
18.3 ± 3.2 b 
17.3 ± 4.7 
*Meant Standard Deviation 
(~ P .( . 02 compared to Intact Control) 
( P <: • OS compared to Intact Control) 
c1-
(meq/l) 
* 
58 "!: 8 
66 ± 6 
65 "!: • 6 
67 ± 9 
* 
8.2 ± 1.7 
5,7±1.0a 
6.6 ± 0.7 
6.9 ± 3.2 
N 
N 
Treatment 
Intact Control 
TABLE 6. 
EXPERIMENT II 
ION CONCENTRATIONS AND Na+/K+ RATIOS THE URINE 
Na+ 
(meq/1) 
* 
124 ± 49 
K+ 
(meq/ 1) 
* 
174 ± 45 
c1-
Cmeq/l) 
* 
117 ± 48 
* 
.73±.21 
--------------------------------------------------------------------------------
Intact Danazol 129 ± 56 177 ± 18 134 ± 46 . 71 ± .15 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Castrate Control 181 ± 44 196 ± 31 211 ± 71 .93 ± .21 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Castrate Danazol 195 ± 34 204 ± 8 .96 ± .19 
*Mean+ Standard Deviation 
ca P, : OS compared to Intact Control) N 
"' 
TABLE 7. 
EXPERIMENT II 
ZONA GLOMERULOSA THICKNESS 
Treatment 
Intact Control 
Intact Danazol 
Castrate Control 
Castrate Danazol 
*Mean~ Standard Deviation 
*Thickness 
(microns) 
51.7 ± 5.1 
40.5 t 5.2 a 
33.0 t 7.2 b 
37.3 t 9.6a 
ca P £. 01 compared to Intact Control) 
(b P<:. 001 compared to Intact Control) 
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DISCUSSION 
In neither experiment were significant changes in 
body weight observed, indicating no anabolic effect at 
the doses administered. It was mentioned previously 
that anabolic effects were usually more prevalent at 
higher doses according to Dmowski (1979). 
Experiment I produced an unexpected increase in 
adrenal weight due to castration alone (Table 1). 
Ovariectomy has been shown by Kitay, et al. (1963) to 
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have an atrophic effect on the adrenal glands due to the 
removal of the stimulatory effect of estrogens on the 
release of ACTH from the pituitary. Experiment II pro-
duced the expected decrease in adrenal weight. The un-
expected result in Experiment I m1ay be attributed to post 
operative stress and the subsequent release of ACTH 
which was still exhibiting a trophic effect on the day 
the animals were sacrificed. More polished surgical 
technique along with the longer post operative period 
before analysis accounts for the more expected observation 
in Experiment II. 
Nonsignificant ovarian weight reduction in Experi-
ment I at all doses and a significant reduction in Exper-
iment II may be attributed to one of three possible 
causes: 1) the antigonadotropic effect of Danazol by way 
of inhibition on the pituitary-ovarian axis as indicated 
by Dmowski (1979), 2) direct inhibition of steroidogen-
esis in the ovary as demonstrated by Barbieri,~ al. 
(1977), or 3) a combination of the two. 
The concentrations of sodium and potassium ions 
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are essential elements in electrolyte metabolism. In the 
kidney nephron sodium tends to be retained in the body 
fluids while potassium tends to be eliminated into the 
urine. Chloride ion concentrations tend to correlate 
with sodium ion concentrations as sodium ions are usually 
retained in the blood or excreted in the urine as sodium 
chloride. Changes in the concentrations of these ions in 
the blood and urine may indicate an effect on aldosterone, 
either in terms of its synthesis, release, or mechanism 
of action. 
In Experiment I the most measurable effects of 
Danazol were observed at a dosage of 4 mg/kg. Significant 
differences in ion concentrations and ratios were noted 
between Danazol injected intact rats and intact controls, 
while differences also occurred between castrate and 
intact rats receiving this same dosage (Table 2 and 3). 
The significant elevation of serum K+ and urine Na+ levels 
. + + 
and a decrease 1n the Na /K ratio in the blood along with 
a nonsignificant elevation in urine Cl- levels indicates 
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that at a dosage of 4 mg/kg in intact rats, sodium chlor-
ide is being eliminated into the urine while K+ is being 
retained in the blood to a greater extent than in control 
rats. These facts along with the significant reduction 
in ovarian weight observed at this dosage led to the 
selection of 4 mg/kg as the optimal dosage to be used in 
Experiment II. 
In Experiment II changes in electrolyte metabolism 
in rat urine and serum (Tables 5 and 6) and the decrease 
in the thickness of the zona glomerulosa (Table 7) in 
intact Danazol treated rats suggests the inhibition of 
aldosterone synthesis. The electrolyte changes were 
indicated by a decrease in the Na+/K+ ratio in the blood 
as well as an elevation in blood K+ levels (Table 5). 
If only electrolyte changes had been observed, influence 
on the renin-angiotensin system might have been suspected, 
The regression of the zona glomerulosa indicates that an 
inhibition of synthesis rather than an inhibition of 
the release of aldosterone is more probable. 
Barbieri, et al. (1977) have shown that Danazol 
inhibits three of the enzymes of steroidogenesis leading 
from pregnenolone to the synthesis of corticosterone in 
rat adrenal cells in vitro. While data presented here 
suggests the inhibition of aldosterone in vivo, it does 
not indicate a mechanism of action. It is not evident 
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whether aldosterone synthesis is inhibited by Danazol's 
inhibition of its precursor production or whether Danazol 
directly inhibits the 18-hydroxylase activity. This could 
be explored in vitro by incubating rat adrenal cells with 
Danazol and radioactive corticosterone as Barbieri, et~-
did in demonstrating the inhibition of the enzymes which 
produced the precursors of aldosterone. The data reveals 
a greater inhibition on the, enzymes the closer you get to 
the synthesis of aldosterone, that is, llS-hydroxylase is 
inhibited more than 21-hydroxylase, which is inhibited 
more than 3S-hydroxysteroid dehydrogenase (See Figure 2). 
Watanuki, et al. (1978) have indicated the very distinct 
possibility that the llS-hydroxylase and 18-hydroxylase 
activities of the zona glomerulosa mitochondria are 
actually catalyzed by only one enzyme instead of two. 
If Danazol inhibits one of the enzyme's activities, there 
is a good possibility that it inhibits the other as well. 
To what extent this may occur is in need of further 
research. 
According to Dmowski (1979) work with radioactive 
Danazol showing greater than plasma concentrations in the 
adrenal glands indicates possibly a direct influence of 
Danazol on the adrenal glands probably by means of bind-
ing to receptor sites. Rifka, et al. (197 8) have reported 
the existence of an adrenal cytosol androgen receptor 
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which may mediate regression of the adrenals. Since 
Danazol is an androgen derivative, one possible explanation 
for adrenal weight loss upon treatment with Danazol is the 
binding of Danazol to this receptor. No significant 
differences were observed .between the castrate controls, 
the castrated treated rats, or thi intact treated rats. 
Ther•efore the effect observed between the intact treated 
and the intact controls may be related to the decrease 
in estrogens rather than a direct effect on the adrenal. 
Estrogens are currently believed to regulate the express-
ion of certain genes and, as a result, subsequent protein 
formation (Turner and Bagnara, 1976). The lack of 
estrogens in castrated rats may cause a reduction of the 
receptors for Danazol, possibly the adrenal androgen 
receptor. Further research with radioactive Danazol's 
ability to bind to this androgen receptor and the 
determination of whether or not castration does, in effect, 
reduce the synthesis of these receptors would clarify this 
issue. 
It should be noted that the length of time of 
administration affected the observed action of Danazol on 
electrolyte metabolism. In the ten day experiment at a 
dosage of 4 mg/kg, castrates exhibited significantly 
higher serum Na+ and lower serum K+ levels than intact 
rats receiving the same dosage (Table 2). Levels in 
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Experiment II, however, were not significantly different. 
The difference in Experiment I may be attributed to the 
post operative increase in aldosterone immediately follow-
ing surgery due to fluid loss. The longer post operative 
period and reduction of post operative stress eliminated 
this effect in Experiment II as no differences in electro-
lyte concentrations or ratios were observed between intact 
or castrate treated rats (Tables 5 and 6). 
Although research has shown Danazol's ability to 
inhibit steroidogenesis in vitro, this thesis presents 
data which suggests the inhibition of aldosterone synthe-
sis by Danazol in vivo in rats. However, more research 
is needed on the in vivo inhibition of steroidogenesis by 
Danazol, particularly in humans. Wentz,~ al. (1975) 
studied adrenal response in.humans at a dosage of 800 
mg/day which is the normal dosage recommended for treat-
ment of endometriosis. They used a synthetic ACTH com-
pound, cosyntropin, to test adrenal response as well as 
a metyrapone challenge which inhibits llS-hydroxylation. 
These. tests were run following chronic Danazol administra-
tion and showed normal cortisol elevation in the blood-
stream compar~d to controls when injected with cosyntro-
pin, and normal ACTH rise following the metyrapone 
challenge. At this dosage in humans, there appears to be 
no evidence of inhibition upon cortisol synthesis. 
Because aldosterone is produced by a different pathway, 
evidence in this thesis indicates a need for research in 
the area of Danazol's effect on the human pathway leading 
to the synthesis of aldosterone. This research would be 
especially important in patients treated -with Danazol 
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who may engage in strenuous activities since they may have 
a tendency to lose large amounts of salt and water from 
their body during activity. 
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